Lumos Pharma Announces Sale of Priority Review Voucher
July 27, 2020 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that it has...
Lumos Pharma Reports First Quarter 2020 Results and Provides Update on Clinical and Corporate Activities
May 28, 2020 16:01 ET
|
Lumos Pharma, Inc.
- Lumos Pharma expects to initiate its Phase 2b LUM-201 trial in Pediatric Growth Hormone Deficiency (PGHD) prior to the end of 2020 - Additional non-dilutive funds expected from anticipated...
Lumos Pharma to Participate in the Jefferies 2020 Healthcare Conference
May 27, 2020 16:27 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the...
Lumos Pharma to Report First Quarter 2020 Financial Results and Host a Conference Call on May 28, 2020
May 26, 2020 10:36 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 26, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report...
Lumos Pharma Hires Biotech Veteran Aaron Schuchart as Chief Business Officer
April 24, 2020 08:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, April 24, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Aaron...
Lumos Pharma Promotes John C. McKew, PhD to Chief Operating Officer and Chief Scientific Officer
April 02, 2020 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, April 02, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced the promotion of...
Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directors Rick Hawkins, CEO, appointed Chairman of the Board
March 30, 2020 08:00 ET
|
NewLink Genetics Corporation
AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced the...
NewLink Genetics Stockholders Approve Merger with Lumos Pharma
March 18, 2020 08:00 ET
|
NewLink Genetics Corporation; Lumos Pharma, Inc.
- Combined company, Lumos Pharma, Inc., to trade on Nasdaq under the stock symbol “LUMO” - Phase 2b trial expected to be initiated mid-2020 evaluating oral therapeutic candidate LUM-201 (ibutamoren)...
NewLink Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
February 28, 2020 09:00 ET
|
NewLink Genetics Corporation
AMES, Iowa, Feb. 28, 2020 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided...
NewLink Genetics Announces Exclusive Worldwide License Agreement with Ellipses Pharma for Development of and Rights to Commercialization of NLG207
December 23, 2019 16:05 ET
|
NewLink Genetics Corporation
AMES, Iowa, Dec. 23, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company has entered into an exclusive worldwide license agreement with Ellipses...